Additional Data From SEQUOIA-HCM Presented at HFSA Annual Scientific Meeting
DAIC
OCTOBER 2, 2024
tim.hodson Wed, 10/02/2024 - 11:08 Sept. 30, 2024 — Cytokinetics, Inc. recently announced that additional analyses synthesizing data from SEQUOIA-HCM ( S afety, E fficacy, and Q uantitative U nderstanding of O bstruction I mpact of A ficamten in HCM ), the Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), were presented virtually at the Heart Failure Society of America (HFSA) Annual Scientific Meeting by Martin Maron, M.D.,
Let's personalize your content